Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03219268
What this trial is testing

MGD013 in Patients With Unresectable or Metastatic Neoplasms

Who this might be right for
Advanced Solid TumorsHematologic NeoplasmsOvarian Cancer+7 more
MacroGenics 277
Testing effectiveness (Phase 2)Looking for participantsNCT06222879
What this trial is testing

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Shandong Suncadia Medicine Co., Ltd. 350
Early research (Phase 1)Ended earlyNCT04042051
What this trial is testing

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer+1 more
Cancer Trials Ireland 2
Testing effectiveness (Phase 2)Looking for participantsNCT06265025
What this trial is testing

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Who this might be right for
Head and Neck CancerMalignant MelanomaColorectal Cancer+3 more
GeneMedicine Co., Ltd. 125
Testing effectiveness (Phase 2)Active Not RecruitingNCT02498613
What this trial is testing

Cediranib in Combination With Olaparib in Advanced Solid Tumors

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Lung Non-Small Cell CarcinomaMetastatic Lung Small Cell Carcinoma+23 more
National Cancer Institute (NCI) 122
Large-scale testing (Phase 3)UnknownNCT05755048
What this trial is testing

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 314
Testing effectiveness (Phase 2)Looking for participantsNCT05741164
What this trial is testing

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+2 more
Emory University 37
Testing effectiveness (Phase 2)Study completedNCT00301899
What this trial is testing

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Who this might be right for
Breast Cancer
National Institutes of Health Clinical Center (CC) 37
Testing effectiveness (Phase 2)Looking for participantsNCT06042894
What this trial is testing

SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 58
Early research (Phase 1)Looking for participantsNCT06331169
What this trial is testing

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 42
Testing effectiveness (Phase 2)Looking for participantsNCT04965766
What this trial is testing

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 139
Testing effectiveness (Phase 2)Looking for participantsNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Large-scale testing (Phase 3)Looking for participantsNCT06081959
What this trial is testing

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Testing effectiveness (Phase 2)Looking for participantsNCT07203729
What this trial is testing

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Who this might be right for
HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 184
Testing effectiveness (Phase 2)Looking for participantsNCT07002177
What this trial is testing

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd. 196
Post-approval studies (Phase 4)Not Yet RecruitingNCT06245824
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 51
Testing effectiveness (Phase 2)Study completedNCT05181462
What this trial is testing

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.

Who this might be right for
Triple Negative Breast Cancer
Cantargia AB 117
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07376629
What this trial is testing

HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Who this might be right for
TNBC
Huabo Biopharm Co., Ltd. 60
Testing effectiveness (Phase 2)Study completedNCT00696072
What this trial is testing

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Who this might be right for
Metastatic Breast Cancer
Bristol-Myers Squibb 120
Next Page